• Home
  • Regenix drugs Ltd
6
Oct
2026
Fiera Milano, Italy
6 Oct 2026 - 8 Oct 2026
stand 14K7
Book a meeting

Regenix drugs Ltd

About Regenix drugs Ltd

Regenix Biosciences Ltd. is a WHO-GMP certified biopharmaceutical manufacturer at MEPZ-SEZ, Chennai, India, specialising in biosimilar insulins, GLP-1 analogues and anticoagulants. Our 30,000 sq.ft. facility is purpose-built for sterile formulation and fill-finish in vials, pre-filled syringes and cartridges, and is DCGI approved, CDSCO registered, ISO 9001:2015 certified and Schedule M compliant. Commercial range, with CTD dossiers: Human Insulin (Regular), Biphasic 30/70, Isophane (NPH), Insulin Glargine, Liraglutide and Enoxaparin Sodium, in vials, PFS, cartridges and disposable pens. We welcome distribution, out-licensing, dossier-supply and contract fill-finish partners.

Read more Show less
Certifications
  • GMP
    GMP
  • ISO
    ISO
More certifications Show less
Sales Markets
Show more Show less
Categories
more categories Show less

Meet us at

  • CPHI Milan 2026

    CPHI Milan 2026

    Fiera Milano, Italy
    6 Oct 2026 - 8 Oct 2026
    stand 14K7
  • Country/Region:
    India
  • Founded:
    2006
  • On CPHI since:
    2024
  • Certificates:
    2
  • Employees:
    50 - 99
Company types
Biopharmaceutical company
Generics/Biosimilars Manufacturer
Primary activities
Biopharmaceutical
Pharmaceutical Company (generic finished products)
Contact info
  • +91 9096192946
  • Website
  • B-26, Phase-II, Zone B, MEPZ-SEZ, West Tambaram, 600045, Chennai, Tamil Nadu, India
Show contact info Hide contact info

Products from Regenix drugs Ltd (6)

  • Biphasic Isophane Insulin Injection BP 30/70 (rDNA origin) 100 IU/mL

    Product Biphasic Isophane Insulin Injection BP 30/70 (rDNA origin) 100 IU/mL

    Pre-mixed recombinant human insulin combining 30% soluble (regular) insulin with 70% isophane (NPH) insulin in a single presentation, delivering bolus and basal cover from one injection. Indicated for type 1 and type 2 diabetes mellitus in patients suited to a twice-daily regimen. Manufactured by Regenix a...
  • Enoxaparin Sodium Injection (Low Molecular Weight Heparin)

    Product Enoxaparin Sodium Injection (Low Molecular Weight Heparin)

    Low molecular weight heparin (LMWH) indicated for the prophylaxis and treatment of venous thromboembolism, including deep vein thrombosis and pulmonary embolism, and for the management of acute coronary syndromes. Enoxaparin offers a predictable anticoagulant response, once or twice daily subcutaneous dosi...
  • Human Insulin Injection BP (Soluble / Regular) 100 IU/mL (rDNA origin)

    Product Human Insulin Injection BP (Soluble / Regular) 100 IU/mL (rDNA origin)

    Short-acting soluble recombinant human insulin for the management of type 1 and type 2 diabetes mellitus, and for use where a rapid onset is required, including intravenous administration under medical supervision in diabetic ketoacidosis and perioperative glycaemic control. Manufactured by Regenix at its ...
  • Insulin Glargine Injection 100 IU/mL (rDNA origin)

    Product Insulin Glargine Injection 100 IU/mL (rDNA origin)

    Long-acting basal insulin analogue providing approximately 24-hour glycaemic control with a flat, peakless pharmacokinetic profile and a correspondingly lower risk of nocturnal hypoglycaemia than NPH insulin. Indicated for type 1 and type 2 diabetes mellitus as once-daily basal therapy. Manufactured by Reg...
  • Isophane Insulin Injection BP (NPH) 100 IU/mL (rDNA origin)

    Product Isophane Insulin Injection BP (NPH) 100 IU/mL (rDNA origin)

    Intermediate-acting isophane (NPH) insulin suspension providing extended basal insulin cover, used alone or in combination with short-acting insulin in type 1 and type 2 diabetes mellitus. Manufactured by Regenix at its dedicated sterile insulin facility in Chennai, India under WHO-GMP and Schedule M. Each...
  • Liraglutide Injection 6 mg/mL (rDNA origin)

    Product Liraglutide Injection 6 mg/mL (rDNA origin)

    Once-daily GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus and for chronic weight management. Liraglutide improves glycaemic control through glucose-dependent insulin secretion, suppression of glucagon release and delayed gastric emptying, with a low intrinsic risk of hypoglycaemia. Ma...

Regenix drugs Ltd Resources (1)